异体胰岛移植:死亡预言的编年史?

IF 2.7 3区 医学 Q1 SURGERY
Transplant International Pub Date : 2025-04-01 eCollection Date: 2025-01-01 DOI:10.3389/ti.2025.14598
Thierry Berney, Olivier Thaunat, Ekaterine Berishvili
{"title":"异体胰岛移植:死亡预言的编年史?","authors":"Thierry Berney, Olivier Thaunat, Ekaterine Berishvili","doi":"10.3389/ti.2025.14598","DOIUrl":null,"url":null,"abstract":"<p><p>Innovative solutions have entered the routine management of patients with type 1 diabetes or are making the headlines and this is shaking the world of beta cell replacement therapies. Above all, allogeneic islet transplantation is enthusiastically doomed to extinction by the aficionados of \"closed loop\" artificial insulin delivery systems or those convinced of the imminent large scale availability of stem-cell derived insulin-producing tissues. This opinion paper will propose that neither will be a universal solution in the very near future and will argue that xenogeneic islet transplantation may be a serious outsider in the race for new therapies. In the meantime, the odds are in favor of allogeneic islet (and pancreas) transplantation remaining first line options in the treatment of complicated type 1 diabetes. There is no question that \"closed loop\" systems have already greatly improved the management of type 1 diabetes, but, while \"unlimited\" sources of insulin-producing cells are jockeying for approval as standard-of-care, these improvements are more likely to drive a shift of indications -from islet transplant alone to simultaneous islet-kidney transplantation- than to herald the demise of islet transplantation.</p>","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"38 ","pages":"14598"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998596/pdf/","citationCount":"0","resultStr":"{\"title\":\"Allogeneic Islet Transplantation: Chronicle of a Death Foretold?\",\"authors\":\"Thierry Berney, Olivier Thaunat, Ekaterine Berishvili\",\"doi\":\"10.3389/ti.2025.14598\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Innovative solutions have entered the routine management of patients with type 1 diabetes or are making the headlines and this is shaking the world of beta cell replacement therapies. Above all, allogeneic islet transplantation is enthusiastically doomed to extinction by the aficionados of \\\"closed loop\\\" artificial insulin delivery systems or those convinced of the imminent large scale availability of stem-cell derived insulin-producing tissues. This opinion paper will propose that neither will be a universal solution in the very near future and will argue that xenogeneic islet transplantation may be a serious outsider in the race for new therapies. In the meantime, the odds are in favor of allogeneic islet (and pancreas) transplantation remaining first line options in the treatment of complicated type 1 diabetes. There is no question that \\\"closed loop\\\" systems have already greatly improved the management of type 1 diabetes, but, while \\\"unlimited\\\" sources of insulin-producing cells are jockeying for approval as standard-of-care, these improvements are more likely to drive a shift of indications -from islet transplant alone to simultaneous islet-kidney transplantation- than to herald the demise of islet transplantation.</p>\",\"PeriodicalId\":23343,\"journal\":{\"name\":\"Transplant International\",\"volume\":\"38 \",\"pages\":\"14598\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998596/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transplant International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/ti.2025.14598\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/ti.2025.14598","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

摘要

创新的解决方案已经进入了1型糖尿病患者的日常管理或正在成为头条新闻,这正在撼动β细胞替代疗法的世界。最重要的是,异体胰岛移植被“闭环”人工胰岛素输送系统的狂热者或那些相信干细胞衍生的胰岛素产生组织即将大规模可用的人热切地注定要灭绝。这篇观点文章将提出,在不久的将来,这两种方法都不会是一个普遍的解决方案,并将论证异种胰岛移植可能是新疗法竞赛中的一个严重的局外人。与此同时,异体胰岛(和胰腺)移植仍然是治疗复杂1型糖尿病的一线选择。毫无疑问,“闭环”系统已经极大地改善了1型糖尿病的管理,但是,当“无限”的胰岛素生产细胞来源正在争取被批准为标准治疗时,这些改进更有可能推动适应症的转变——从单独的胰岛移植到同时的胰岛肾移植——而不是预示着胰岛移植的消亡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Allogeneic Islet Transplantation: Chronicle of a Death Foretold?

Innovative solutions have entered the routine management of patients with type 1 diabetes or are making the headlines and this is shaking the world of beta cell replacement therapies. Above all, allogeneic islet transplantation is enthusiastically doomed to extinction by the aficionados of "closed loop" artificial insulin delivery systems or those convinced of the imminent large scale availability of stem-cell derived insulin-producing tissues. This opinion paper will propose that neither will be a universal solution in the very near future and will argue that xenogeneic islet transplantation may be a serious outsider in the race for new therapies. In the meantime, the odds are in favor of allogeneic islet (and pancreas) transplantation remaining first line options in the treatment of complicated type 1 diabetes. There is no question that "closed loop" systems have already greatly improved the management of type 1 diabetes, but, while "unlimited" sources of insulin-producing cells are jockeying for approval as standard-of-care, these improvements are more likely to drive a shift of indications -from islet transplant alone to simultaneous islet-kidney transplantation- than to herald the demise of islet transplantation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Transplant International
Transplant International 医学-外科
CiteScore
4.70
自引率
6.50%
发文量
211
审稿时长
3-8 weeks
期刊介绍: The aim of the journal is to serve as a forum for the exchange of scientific information in the form of original and high quality papers in the field of transplantation. Clinical and experimental studies, as well as editorials, letters to the editors, and, occasionally, reviews on the biology, physiology, and immunology of transplantation of tissues and organs, are published. Publishing time for the latter is approximately six months, provided major revisions are not needed. The journal is published in yearly volumes, each volume containing twelve issues. Papers submitted to the journal are subject to peer review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信